Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “TARTRATES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 73 records · Page 4Linked to original sources
PubMed1991

Ion-chromatographic determination of L-tartrate in urine samples.

We propose using ion chromatography to determine tartrate concentration in urine. A 100-microL sample of urine is diluted and injected into the chromatograph. Tartrate is eluted within 11.5 min as a distinct and well-resolved peak. The sensitivity of the standard procedure (signal-to-noise ratio, 3/1) is 30 mumol/L. The intra-run and interrun coefficients of variation are 2.5% and 4.1%, respectively. Mean analytical recovery of known amounts of added tartrate ranges between 94.2% and 104.0%. We investigated the specificity of the procedure by analyzing urine containing added dicarboxylic acids structurally related to tartrate. The reliability of the procedure makes it suitable for investigating tartrate metabolism, e.g., the potential role of tartrate as an inhibitor of crystallization in calcium nephrolithiasis.

Adult↗
PubMed1978

Spectrophotometric determination of pyrantel tartrate in swine feeds by method of standard additions: collaborative study.

The spectrophotometric method for pyrantel tartrate in swine feeds was collaboratively studied. Twenty-seven laboratories assayed feeds containing 0.0103, 0.0965, and 0.7902% pyrantel tartrate. Repeatability (sigmao) and reproducibility (sigmax) standard deviations were: sigmao = 0.00068%, sigmax = 0.00105% (10% of grand mean) for 0.0103% pyrantel tartrate level; sigmao - 0.0065%, sigmax = 0.0090% (10% of grand mean) for 0.0965% pyrantel tartrate level; and sigmao = 0.0415%, sigmax = 0.0743% (10% of grand mean) for 0.7902% pyrantel tartrate level. The mean theoretical recovery values for feeds containing 0.0103, 0.0965, and 0.7902% were 100, 97, and 96%, respectively. The method was adopted as official first action for feeds or concentrates containing 0.0106-0.8811% pyrantel tartrate.

Animal Feed↗
PubMed1997

Acute upper extremity ischemia during concomitant use of ergotamine tartrate and ampicillin.

Individual hypersensitivity to the vasoconstrictor effects of ergotamine tartrate has been observed even at doses within recommended limits. Hypersensitivity can be induced by concomitant use with other drugs. The best-documented example of drug-induced hypersensitivity to ergotamine tartrate involves antibiotics of the macrolides class. The mechanism underlying this interaction appears to be interference with metabolism of ergotamine tartrate by the liver. In the present report we describe a case of upper extremity ischemia during concomitant use of ergotamine tartrate and ampicillin. The fact that the effect was not dose-dependent, disappeared when administration of ampicillin was discontinued, and reappeared when administration of ampicillin was resumed suggests that the underlying mechanism in our patient was immunologic. Since immunologic hypersensitivity to the vasoconstrictor effects of ergotamine tartrate is unpredictable, great caution and close surveillance is advisable when ergotamine tartrate is used in association with other drugs.

Ampicillin↗
PubMed2005

Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate.

BACKGROUND: The Carvedilol or Metoprolol European Trial (COMET) demonstrated improved survival with carvedilol vs. metoprolol tartrate in patients with heart failure. The benefits of carvedilol in typical clinical practice in the United States are unknown. METHODS: Using data from a large United States health-insurance claims database, we conducted a retrospective study to compare the risks of death and hospitalization and the cost of inpatient care in heart failure patients receiving carvedilol vs. metoprolol tartrate. The sample consisted of all patients with a prescription for carvedilol or metoprolol tartrate between September 1997 and August 2000 who also had a prior medical encounter with a primary diagnosis of heart failure, prior prescriptions for a loop diuretic and an angiotensin-converting enzyme inhibitor, and no prior prescriptions for a beta-blocker. RESULTS: We identified 887 carvedilol patients and an equal number that received metoprolol tartrate. Mean duration of follow-up was 11 months (maximum, 36 months). Controlling for baseline characteristics using a Cox proportional hazards model, carvedilol was independently associated with a reduced risk of all-cause mortality (hazard ratio 0.78; 95% confidence interval 0.61 to 0.99) and all-cause hospitalization (hazard ratio 0.77; 95% confidence interval 0.67 to 0.90). In a propensity-matched sample of carvedilol and metoprolol tartrate patients (n = 564 each), expected costs of inpatient care at 36 months were 10,509 US dollars lower with carvedilol (95% confidence interval 2934-18,085 US dollars). CONCLUSIONS: Use of carvedilol rather than metoprolol tartrate may improve survival and reduce costs of care in heart failure patients in typical clinical practice in the United States.

Adrenergic beta-Antagonists↗
PubMed1987

[Effects of ifenprodil tartrate on erythrocyte deformability and cerebral blood flow].

Effects of ifenprodil tartrate on whole blood filtrability ex vivo in rats was investigated by a standard technique for measuring whole blood filtration time passed through a filter (5 micron). Ifenprodil tartrate was observed to reduce the filtration time dose-responsively. This effect was especially evident at 20 mg/kg (P less than 0.05). On the other hand, no effect on the hematocrit value, plasma concentration of fibrinogen, erythrocyte count or mean cellular volume of erythrocytes was observed. These results indicated the increasing effects ex vivo of ifenprodil tartrate on erythrocyte deformability. The ex vivo effects on erythrocyte deformability was manifested without changing the ATP contents, ATP/ADP ratio or adenylate energy charge in erythrocytes; and a phenothiazine-like amelioration in the shape of crenated erythrocytes was observed. These results suggested that the effect of ifenprodil tartrate on erythrocyte deformability ex vivo might be due to direct action on the erythrocyte membrane. At 0.3 mg/kg, i.v., ifenprodil tartrate significantly (P less than 0.05) increased the blood flow in the hypothalamus of conscious rats. Thus, it was indicated that ifenprodil tartrate, which increases the erythrocyte deformability and the cerebral blood flow, is useful for the therapeutic treatment of cerebrovascular accidents.

Adenine Nucleotides↗
PubMed1994

Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.

The compatibility of vinorelbine tartrate with selected drugs during simulated Y-site administration was studied. A 5-mL sample of vinorelbine tartrate 1 mg/mL in 0.9% sodium chloride injection was combined with a 5-mL sample of each of 91 other drugs at concentrations used clinically. Each combination was prepared in duplicate, with the order of mixing being reversed between the two; storage was in constant fluorescent light at 22 degrees C. The admixtures were examined visually in normal fluorescent light and with a Tyndall beam at zero, one, and four hours after preparation. A turbidimeter was used to measure the turbidity of each drug combination at the same intervals. Samples showing visual or turbidimetric evidence of incompatibility were subjected to particle counting and sizing. The majority of the drugs tested were compatible with vinorelbine tartrate; most combinations had a turbidity of less than 0.1 nephelometric turbidity unit. Turbidity measurements showed that cefazolin sodium, ceforanide, and cefuroxime sodium were incompatible with vinorelbine tartrate. Visual observation showed incompatibility of vinorelbine tartrate with acyclovir sodium, aminophylline, amphotericin B, ampicillin sodium, cefoperazone sodium, ceforanide, cefotetan sodium, ceftriaxone sodium, fluorouracil, furosemide, ganciclovir sodium, methylprednisolone sodium succinate, mitomycin, piperacillin sodium, sodium bicarbonate, thiotepa, and trimethoprimsulfamethoxazole. Vinorelbine tartrate 1 mg/mL in 0.9% sodium chloride injection was compatible with the majority of the drugs tested for up to four hours at 22 degrees C but was incompatible with 19 drugs.

Drug Compounding↗
PubMed1989

Calcium tartrate gel.

A method for preparation of a gel for chromatography has been developed. The adsorbent is calcium tartrate treated with potassium phosphate. By changing the temperature of synthesis (10-65 degrees C) and concentration of the salts (calcium chloride and sodium potassium tartrate) from 0.3 to 3.0 M, we have been able to prepare adsorbent crystals of definite sizes in the range 35-200 microns. In all cases, for synthesis of adsorbent, the Ca2+/K+Na+ ratio was greater than 1. After treatment of calcium tartrate crystals with 0.075-1.5 M potassium phosphate at 80-100 degrees C and pH 8.5-9.0, an appropriate chromatographic adsorbent was prepared. The chromatographic properties of calcium tartrate gel have been studied. The adsorbent permits flow rates of 25-150 ml/h, depending on the particle size. The capacity of calcium tartrate gel for binding BSA, RNA, and DNA was similar to that of Tiselius' hydroxyapatite (A. Tiselius, S. Hjerten, O. Levin (1956) Arch. Biochem. Biophys. 65, 132-155). The spheric shape of gel particles permits uniform and compact packing of adsorbent under the conditions of column chromatography.

Calcium↗
PubMed1976

Quantitative thin-layer chromatographic analysis of ergotamine tartrate and caffeine in the nanogram range.

Direct, quantitative, thin-layer chromatographic methods for the determination of ergotamine tartrate and caffeine in the presence of each other in blood and in pharmaceutical preparations are described. The blood is centrifuged, the plasma decanted from the coagulum and deproteinized with acetone-methanol. After removal of the solvent mixture, the active ingredients are extracted from the remaining aqueous solution with chloroform. In the case of the pharmaceutical preparations, the active ingredients are also extracted with chloroform or methanol. Ergotamine tartrate and caffeine are separated on pre-coated silica gel 60 F254 plates and measured directly on the thin-layer plate, ergotamine tartrate being determined by the fluorescence method, excitation wavelength 365 nm, at lambdamax.=450 nm and caffeine by the reflactance method at lambdamax.=274 nm. The analytical methods are suitable for the bioavailability studies of these drugs in blood as they enable the determination of 20 ng ergotamine tartrate with a coefficient of variation of 6.7% and the determination of 200 ng caffeine with a coefficient of variation of 6.1%. The methods have also proved useful in the determination of the active ingredients of drug forms such as tablets and suppositories and can be well reproduced with a maximum coefficient of variation of 4.9% for ergotamine tartrate and 3.5% for caffeine.

Biological Availability↗
PubMed1996

Characterization and distribution of tartrate utilization genes in the grapevine pathogen Agrobacterium vitis.

Agrobacterium vitis is a common pathogen of grapevine. Most strains utilize tartrate, an abundant compound in grapevine. Strain AB3 carries two tartrate utilization (or TAR) regions: TAR-I (on the large pTrAB3 plasmid) and TAR-II (on the AB3 Ti plasmid). TAR-I and TAR-II were structurally and functionally analyzed and are similar to the TAR-III region from the tartrate utilization plasmid pTrAB4 of the nopaline-type A. vitis strain AB4 (Crouzet and Otten, J. Bacteriol. 1995, 177:6518-6526). The minimal tartrate utilization region of TAR-I contains four genes (ttuA-ttuD). The ttuC gene is homologous to the tartrate dehydrogenase gene from Pseudomonas putida. Outside the minimal region a second ttuC-like gene is found (ttuC') which is transcribed and complements a ttuC mutant. Most grapevine isolates carry one or two of the three characterized TAR regions and show a considerable degree of polymorphism around these regions.

DNA Mutational Analysis↗
PubMed2006

Isolation of Salmonella enterica subspecies enterica serovar Paratyphi B dT+, or Salmonella Java, from Indonesia and alteration of the d-tartrate fermentation phenotype by disrupting the ORF STM 3356.

Salmonella enterica subspecies enterica serovar Paratyphi B [O1,4,(5),12 : Hb : 1,2] can cause either an enteric fever (paratyphoid fever) or self-limiting gastroenteritis in humans. The d-tartrate non-fermenting variant S. enterica subsp. enterica serovar Paratyphi B dT- (S. Paratyphi B) is the causative agent of paratyphoid fever, and the d-tartrate fermenting variant S. enterica subsp. enterica serovar Paratyphi B dT+ (S. Paratyphi B dT+; formerly called Salmonella Java) causes gastroenteritis. S. Java is currently recognized as an emerging problem worldwide. Twelve dT+ S. Java isolates were collected in Indonesia between 2000 and 2002. One-third of them contained Salmonella genomic island 1 (SGI1), which gives the multidrug-resistant phenotype to the bacteria. In this study, a PCR-based method to detect a single nucleotide difference responsible for the inability to ferment d-tartrate, reported elsewhere, was validated. The d-tartrate fermenting phenotype of S. Java was converted to the non-fermenting phenotype by the disruption of the ORF STM 3356, and the d-tartrate non-fermenting phenotype of the ORF STM 3356-disrupted strain and the dT- reference strain was changed to the dT+ phenotype by complementing ORF STM 3356 in trans. The results show that the dT+ phenotype requires a functional product encoded by STM 3356, and support the use of the PCR-based discrimination method for S. Paratyphi B and S. Java as the standard differentiation method.

Anti-Bacterial Agents↗
PubMed1995

Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells.

Cross-resistance between cisplatin (DDP) and metalloid salts in human cells was sought on the basis that mechanisms that mediate metalloid salt cross-resistance in prokaryotes are evolutionarily conserved. Two ovarian and two head and neck carcinoma cell lines selected for DDP resistance were found to be cross-resistant to antimony potassium tartrate, which contains trivalent antimony. The DDP-resistant variant 2008/A was also cross-resistant to arsenite but not to stibogluconate, which contains pentavalent antimony. A variant selected for resistance to antimony potassium tartrate was cross-resistant to DDP and arsenite. Resistance to antimony potassium tartrate and arsenite was of a similar magnitude (3-7-fold), whereas the level of resistance to DDP was greater (17-fold), irrespective of whether the cells were selected by exposure to DDP or to antimony potassium tartrate. In the resistant sublines, uptake of [3H]-dichloro(ethylenediamine) platinum(II) was reduced to 41-52% of control, and a similar deficit was observed in the accumulation of arsenite. We conclude that DDP, antimony potassium tartrate, and arsenite all share a common mechanism of resistance in human cells and that this is due in part to an accumulation defect.

Anions↗
PubMed2002

Effects of meluadrine tartrate on maternal metabolic responses and fetal hemodynamics in pregnant goats.

This study was designed to elucidate the effects of meluadrine tartrate on maternal metabolic responses and fetal hemodynamics in unanesthetized, chronically instrumented pregnant goats. After the administration of meluadrine tartrate to pregnant goats or directly to fetuses, changes in heart rate (HR), arterial blood pressure and arterial blood pH, gasses, electrolytes and metabolic responses were measured. The constant administration of meluadrine tartrate (0.1 microg. kg(-)(1). min(-)(1)) to pregnant goats resulted in the increases of maternal HR, glucose and free fatty acid and the decrease of maternal blood K(+) concentration. The direct escalating administration of meluadrine tartrate (0.01, 0.03 and 0.1 microg. kg(-)(1). min(-)(1)) did not increase the fetal HR, while ritodrine hydrochloride (0.3, 1 and 3 microg. kg(-)(1). min(-)(1)) to fetuses increased the fetal HR dose-dependently. The present study suggests that meluadrine tartrate has a mild influence relative to the effects of ritodrine to the maternal metabolic responses and fetal cardiovascular function.

Adrenergic beta-Agonists↗
PubMed1981

High performance liquid chromatographic method fo pyrantel tartrate in swine feeds and supplements.

A new method for the determination of pyrantel tartrate in swine feed an supplements has been developed because the current official AOAC method is not applicable to feeds co-medicated with tylosin. The new method involves: (a) leaching of drug from feed with methanolic NaCl solution, (b) removal of interfering substances by ion pair liquid-liquid extraction and high performance liquid chromatography, and (c) quantitation of pyrantel tartrate by monitoring the ultraviolet absorption of the effluent stream at 313nm. The method of standard addition is used to compensate for the effect of the feed matrix on drug recovery. No interference is encountered from tylosin, carbadox, lincomycin, non-drug components of feeds and supplements, or potential degradation products of pyrantel tartrate, i.e., cis isomer of pyrantel tartrate and (E)-N-(3-methylaminopropyl)-2-thiopheneacrylamide. Results for the assay of 3 lots each of feeds and supplements containing 0.0106 and 0.106% pyrantel tartrate, respectively, were within +/-4% of label claim. Coefficients of variation ranged from 1.6 to 1.8% for feeds and from 1.9 to 3.9% for supplements.

Animal Feed↗
PubMed1978

[Toxicity studies of Pharmachem's tylosin tartrate for broilers and turkeys].

Studied were the acute, subchronic, and chronic toxicity of the Pharmachim tylosin tartrate as well as the tolerance of chicken broilers and turkeys. The mean lethal dose of the antibiotic at subcutaneous application to 28-32 day-old broilers was 620 mg/kg; the oral dose was 1500 mg/kg. In the case of 42-45-day-old broilers these values were 740 and 5400 mg/kg. The LD50 at i/v infusion for 75-77-day-old ones was 48 mg/kg. Beside the age and route of introduction toxicity was found to depend on the initial biologic activity of tylosin tartrate. The subcutaneous injection of tylosin tartrate at the rate of 30 mg/kg for 20 days did not lead to changes in the appetite, behaviour, growth, and structure of viscera. A 42-day treatment at the same rate, however, resulted in slightly manifested and fully reversible dystrophic changes in the liver and kidneys. Higher doses (90 and 150 mg/kg) led to transient depression, stunting of growth, and a rise of the urea level and the activity of blood transaminases as well as to moderate destructive changes in the liver and kidneys. The stimulation of growth and the improvement of feed conversion (without deviations in the clinical and biochemical indices of the blood and the structure and development of the viscera in broilers) were recorded after the application of a water-soluble formula of tylosin tartrate for a period of 98 days offered via the drinking water in amounts equal to or exceeding 2 to 4 times the ED50. Turkeys' tolerance for the preparation was evaluated as very good so far as single i/m injective applications were concerned in doses exceeding 3, 5, and 10 times the average effective rates, no differences in this respect being noted with the comparative use of tylosin tartrate produced by the Elanco firm.

Animals↗
PubMed2000

A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma.

BACKGROUND: The aim of the current trial was to assess the efficacy and toxicity of weekly intravenous vinorelbine tartrate with daily oral tamoxifen in the treatment of patients with advanced or metastatic malignant melanoma. METHODS: Thirty-one patients were treated with vinorelbine tartrate, 30 mg/m(2) intravenously, weekly every 13 weeks and then every 2 weeks thereafter until progression of disease or severity of toxicity warranted discontinuation. Tamoxifen, 10 mg orally, twice a day was administered daily starting on Day 1 of chemotherapy with vinorelbine tartrate. Thirty patients had cutaneous melanoma with metastases and 1 patient had ocular melanoma with metastases. Eight patients had received prior chemotherapy. RESULTS: Of the 30 evaluable patients with cutaneous melanoma, 6 achieved a partial response, for an overall response rate of 20% (95% confidence interval, 7-38%). There was no response in the patient with ocular melanoma. Major sites of response include the adrenal gland, lung, tonsil, and cutaneous/subcutaneous tissues. Three patients had a prolonged duration of response lasting > or = 12 months. Side effects generally were mild and tolerable. Grade 3 or 4 hematologic toxicity occurred in 26% and 13% of patients, respectively. Nonhematologic toxicity included mild fatigue, paresthesia, and local arm discomfort from infusion. CONCLUSIONS: Weekly intravenous vinorelbine tartrate plus daily oral tamoxifen appears to be active in the treatment of patients with malignant melanoma. Further clinical trials in malignant melanoma patients treated with vinorelbine tartrate and tamoxifen appear warranted.

Administration, Oral↗
PubMed1980

Mild analgesics as an alternative to ergotamine in migraine. A comparative trial with acetylsalicylic acid, ergotamine tartrate, and a dextropropoxyphene compound.

The effect of ergotamine tartrate was compared with that of acetylsalicylic acid and a dextropropoxyphene compound (Doleron novum) on 525 acute migraine attacks in a double-blind crossover study of 25 adult female patients. Ergotamine tartrate and the dextropropoxyphene compound were equally effective and significantly superior to acetylsalicylic acid in preventing the attacks entirely. If the attacks were only partially prevented, the dextropropoxyphene compound was significantly superior to acetylsalicylic acid in making the attacks shorter and milder, while ergotamine tartrate did not differ significantly from acetylsalicylic acid or the dextropropoxyphene compound. The incidence of nausea and vomiting was lowest during treatment with the dextropropoxyphene compound. In the patients' overall preference, the dextropropoxyphene compound and ergotamine tartrate were significantly superior to acetyl-salicylic acid. In acute migraine the combination of dextropropoxyphene, a centrally acting analgesic, with acetylsalicylic acid and phenazone gives an alternative to ergotamine tartrate that is equally effective and causes less nausea and vomiting.

Adult↗
PubMed1997

Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration.

Ulcerative colitis is predominantly a disease of nonsmokers, and transdermal nicotine is therapeutic but often results in adverse reactions. Colonic administration of nicotine tartrate as a liquid enema could decrease systemic nicotine absorption and adverse reactions. The purpose of the current study was to determine the bioavailability and pharmacokinetic parameters of nicotine after administration by hydrophilic liquid enema (acidic and basic), hydrophobic liquid enema (acidic and basic), and by oral and intravenous routes. Thirty healthy volunteers received 45 micrograms nicotine base/kg (as nicotine tartrate) in one of five formulations (each n = 6): hydrophilic acidic liquid enema, hydrophilic basic liquid enema, hydrophobic acidic liquid enema, hydrophobic basic liquid enema, and oral solution. All participants also received 15 micrograms nicotine base/kg (as nicotine tartrate) intravenously during a separate study period. Serum concentrations of nicotine were determined by gas chromatography with mass spectrometry. The mean (+/-SD) bioavailabilities of nicotine after administration in the liquid enema formulations (hydrophilic acidic 17 +/- 18%, hydrophilic basic 16 +/- 16%, hydrophobic acidic 25 +/- 17%, hydrophobic basic 15 +/- 12%) were similar to the bioavailability of nicotine after administration by oral solution (20 +/- 25%). The bioavailabilities of nicotine for all five nonintravenous formulations were significantly less than for intravenous nicotine (100%). Serum concentrations of nicotine did not predict adverse reactions. Nicotine tartrate administered as either a liquid enema or as an oral solution had low bioavailability and was well tolerated. The therapeutic potential of nicotine tartrate liquid enemas, which can potentially limit toxicity by local (colonic) delivery of high doses of nicotine should be investigated in patients with left-sided ulcerative colitis.

Administration, Oral↗
PubMed2004

Pharmacokinetic evaluation of guar gum-based three-layer matrix tablets for oral controlled delivery of highly soluble metoprolol tartrate as a model drug.

The objective of the present study is to carry out pharmacokinetic evaluation of oral controlled release formulation (guar gum-based three-layer matrix tablets) containing highly soluble metoprolol tartrate as a model drug. Six healthy volunteers participated in the study, and a two-way crossover design was followed. The plasma concentration of metoprolol tartrate was estimated by reverse-phase HPLC. The pharmacokinetic parameters were calculated from the plasma concentration of metoprolol tartrate versus time data. The delayed T(max) lower C(max) decreased K(a) unaltered bioavailability and prolonged t(1/2) indicated a slow and prolonged release of metoprolol tartrate from guar gum three-layer matrix tablets in comparison with the immediate release tablet dosage form. The results of the study indicated that guar gum three-layer matrix tablets were able to provide oral controlled delivery of highly water-soluble drug such as metoprolol tartrate in humans.

Administration, Oral↗